FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135907046> ?p ?o ?g. }

• W3135907046 endingPage "1415" @default.
• W3135907046 startingPage "1407" @default.
• W3135907046 abstract "<h3>Purpose</h3> Many muscle-invasive bladder cancers are hypoxic, which limits the efficacy of radiation therapy. Hypoxia modification using carbogen and nicotinamide has been tested in a phase 3 trial, Bladder Carbogen Nicotinamide. We present mature follow-up data with biomarker predictions of outcomes. <h3>Methods and Materials</h3> Bladder Carbogen Nicotinamide is a prospective, phase 3, multicenter, randomized, 2-arm, nonblinded clinical trial. Participants were randomized to receive radical radiation therapy (RT; control arm) alone or with the addition of carbogen (98% O2; 2% CO2) and nicotinamide (CON). Patients with muscle-invasive or high-grade non–muscle invasive bladder cancer were included. Tumor tissue was collected at entry and was analyzed for tumor necrosis, hypoxia (24-gene signature), and basal and luminal tumor molecular subtypes. Overall survival (OS) and disease-free survival and relationships with biomarker status outcomes are analyzed using multivariable Cox regression and log-rank analysis. <h3>Results</h3> We analyzed 333 patients with a median follow-up of 10.3 years. The 10-year OS rates were 30% (95% confidence interval [CI], 0.23-0.39) in RT + CON patients and 24% (95% CI, 0.18-0.33) in the RT-alone patients (hazard ratio [HR], 0.80; 95% CI, 0.61-1.04; <i>P =</i> .08). The greatest benefit from CON was seen in patients with tumor necrosis (n = 79; 5-year OS, 53% vs. 33% in patients without tumor necrosis; HR, 0.59; 95% CI, 0.36-0.99; <i>P</i> = .04). Cases with a high hypoxia gene score (n = 75) had a 5-year OS rate of 51%, compared to 34% for a low score (HR, 0.64; 95% CI, 0.38-1.08; <i>P</i> = .09); those with the basal molecular subtype (n = 70) had a 5-year OS rate of 58%, compared to 38% for those with the luminal subtype (HR, 0.58; 95% CI, 0.32-1.06; <i>P</i> = .08). <h3>Conclusions</h3> Although the improvement in long-term OS in the whole population is not statistically significant, patients selected by necrosis and high hypoxia gene score benefitted from hypoxia modification." @default.
• W3135907046 created "2021-03-15" @default.
• W3135907046 creator A5018745113 @default.
• W3135907046 creator A5020453607 @default.
• W3135907046 creator A5041859071 @default.
• W3135907046 creator A5048550515 @default.
• W3135907046 creator A5061759470 @default.
• W3135907046 creator A5066893635 @default.
• W3135907046 creator A5079894409 @default.
• W3135907046 creator A5089242256 @default.
• W3135907046 creator A5091263008 @default.
• W3135907046 date "2021-08-01" @default.
• W3135907046 modified "2023-10-01" @default.
• W3135907046 title "Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399)" @default.
• W3135907046 cites W1987912497 @default.
• W3135907046 cites W1993323132 @default.
• W3135907046 cites W2004505677 @default.
• W3135907046 cites W2067964015 @default.
• W3135907046 cites W2071123870 @default.
• W3135907046 cites W2071335476 @default.
• W3135907046 cites W2123838717 @default.
• W3135907046 cites W2125675894 @default.
• W3135907046 cites W2134775780 @default.
• W3135907046 cites W2138550913 @default.
• W3135907046 cites W2166453367 @default.
• W3135907046 cites W2605993275 @default.
• W3135907046 cites W2607756307 @default.
• W3135907046 cites W2888477550 @default.
• W3135907046 cites W2894918092 @default.
• W3135907046 doi "https://doi.org/10.1016/j.ijrobp.2021.03.001" @default.
• W3135907046 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33689854" @default.
• W3135907046 hasPublicationYear "2021" @default.
• W3135907046 type Work @default.
• W3135907046 sameAs 3135907046 @default.
• W3135907046 citedByCount "23" @default.
• W3135907046 countsByYear W31359070462021 @default.
• W3135907046 countsByYear W31359070462022 @default.
• W3135907046 countsByYear W31359070462023 @default.
• W3135907046 crossrefType "journal-article" @default.
• W3135907046 hasAuthorship W3135907046A5018745113 @default.
• W3135907046 hasAuthorship W3135907046A5020453607 @default.
• W3135907046 hasAuthorship W3135907046A5041859071 @default.
• W3135907046 hasAuthorship W3135907046A5048550515 @default.
• W3135907046 hasAuthorship W3135907046A5061759470 @default.
• W3135907046 hasAuthorship W3135907046A5066893635 @default.
• W3135907046 hasAuthorship W3135907046A5079894409 @default.
• W3135907046 hasAuthorship W3135907046A5089242256 @default.
• W3135907046 hasAuthorship W3135907046A5091263008 @default.
• W3135907046 hasBestOaLocation W31359070462 @default.
• W3135907046 hasConcept C121608353 @default.
• W3135907046 hasConcept C126322002 @default.
• W3135907046 hasConcept C126894567 @default.
• W3135907046 hasConcept C143998085 @default.
• W3135907046 hasConcept C168563851 @default.
• W3135907046 hasConcept C173622453 @default.
• W3135907046 hasConcept C178790620 @default.
• W3135907046 hasConcept C181199279 @default.
• W3135907046 hasConcept C185592680 @default.
• W3135907046 hasConcept C207103383 @default.
• W3135907046 hasConcept C2779081379 @default.
• W3135907046 hasConcept C2779728014 @default.
• W3135907046 hasConcept C2780352672 @default.
• W3135907046 hasConcept C44249647 @default.
• W3135907046 hasConcept C50382708 @default.
• W3135907046 hasConcept C509974204 @default.
• W3135907046 hasConcept C540031477 @default.
• W3135907046 hasConcept C55493867 @default.
• W3135907046 hasConcept C71924100 @default.
• W3135907046 hasConcept C7836513 @default.
• W3135907046 hasConcept C90924648 @default.
• W3135907046 hasConceptScore W3135907046C121608353 @default.
• W3135907046 hasConceptScore W3135907046C126322002 @default.
• W3135907046 hasConceptScore W3135907046C126894567 @default.
• W3135907046 hasConceptScore W3135907046C143998085 @default.
• W3135907046 hasConceptScore W3135907046C168563851 @default.
• W3135907046 hasConceptScore W3135907046C173622453 @default.
• W3135907046 hasConceptScore W3135907046C178790620 @default.
• W3135907046 hasConceptScore W3135907046C181199279 @default.
• W3135907046 hasConceptScore W3135907046C185592680 @default.
• W3135907046 hasConceptScore W3135907046C207103383 @default.
• W3135907046 hasConceptScore W3135907046C2779081379 @default.
• W3135907046 hasConceptScore W3135907046C2779728014 @default.
• W3135907046 hasConceptScore W3135907046C2780352672 @default.
• W3135907046 hasConceptScore W3135907046C44249647 @default.
• W3135907046 hasConceptScore W3135907046C50382708 @default.
• W3135907046 hasConceptScore W3135907046C509974204 @default.
• W3135907046 hasConceptScore W3135907046C540031477 @default.
• W3135907046 hasConceptScore W3135907046C55493867 @default.
• W3135907046 hasConceptScore W3135907046C71924100 @default.
• W3135907046 hasConceptScore W3135907046C7836513 @default.
• W3135907046 hasConceptScore W3135907046C90924648 @default.
• W3135907046 hasFunder F4320319985 @default.
• W3135907046 hasIssue "5" @default.
• W3135907046 hasLocation W31359070461 @default.
• W3135907046 hasLocation W31359070462 @default.
• W3135907046 hasLocation W31359070463 @default.
• W3135907046 hasOpenAccess W3135907046 @default.
• W3135907046 hasPrimaryLocation W31359070461 @default.

• next